AZ Faces DOJ Probe Into Brilinta Trial

Drug Industry Daily
A A
The Department of Justice is investigating a Phase III study of AstraZeneca’s (AZ) heart drug Brilinta, which analysts and experts say could revolve around allegations of data falsification.

To View This Article:

Login

Subscribe To Drug Industry Daily